Last reviewed 2026-05-19 · How we verify

Tibicorten (TRIAMCINOLONE BENETONIDE)

Phase 2 active Small molecule ✓ Verified May 2026 Quality 19/100

Tibicorten (generic name: TRIAMCINOLONE BENETONIDE) is a Corticosteroid drug. It is currently in Phase 2 development.

Tibicorten works by binding to glucocorticoid receptors in the body, which reduces inflammation and immune response.

Tibicorten is a small molecule medication. It is also known as Triamcinolone benetonide.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TRIAMCINOLONE BENETONIDE
Drug class	Corticosteroid
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Imagine your body's immune system as a fire alarm that goes off when it senses something wrong. Tibicorten is like a fire alarm silencer that reduces the alarm's sensitivity, so it doesn't go off as easily. This helps to reduce inflammation and swelling, but it can also make it harder for your body to fight off infections.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tibicorten CI brief — competitive landscape report
Tibicorten updates RSS · CI watch RSS

Frequently asked questions about Tibicorten

What is Tibicorten?

Tibicorten (TRIAMCINOLONE BENETONIDE) is a Corticosteroid drug.

How does Tibicorten work?

Tibicorten works by binding to glucocorticoid receptors in the body, which reduces inflammation and immune response.

What is the generic name of Tibicorten?

TRIAMCINOLONE BENETONIDE is the generic (nonproprietary) name of Tibicorten.

What drug class is Tibicorten in?

Tibicorten belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is Tibicorten in?

Tibicorten is in Phase 2.

Drug class: All Corticosteroid drugs
Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing